Fact CheckerSign in

NCT07577596RecruitingPhase 4

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)

Source: ClinicalTrials.gov · Last updated 6 Jul 2026

Brief summary (registry, in English)

Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine. Furosemide is a commonly used water-removing medicine that is given into a vein to treat fluid overload. It can be given in different ways. One way is as a continuous infusion, where the medicine is given slowly over time through a pump. Another way is as repeated injections given several times a day. It is not known whether one of these ways is better than the other for removing excess fluid in people with acute heart failure. The purpose of this study is to compare two ways of giving furosemide into a vein: Continuous infusion started with an initial extra dose, and bolus injections given three times a day. About 436 adults admitted to hospitals in Denmark with acute heart failure and fluid overload will take part. Participants will be randomly assigned to one of the two treatment groups. This means that chance will decide which treatment method each participant receives. The main thing the researchers will measure is how much body weight participants lose about 3 days after randomization. Weight loss is used as a measure of how much excess fluid has been removed.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
436 (estimated)
First submitted
28 Apr 2026
Start date
30 Jun 2026
Primary completion date
1 Sept 2027
Lead sponsor
University of Aarhus
NCT number
NCT07577596
EU CT number
2025-523589-26-00

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 436
  • From 30 Jun 2026 to the primary completion date, 1 Sept 2027
  • 7 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patient requiring treatment with inotropes or vasopressors
  • Current or planned use of renal replacement therapy or ultrafiltration
  • Patient with a renal transplant

Other illness

  • Allergy to furosemide and its components

Lab values

  • Severe hypokalaemia, defined as potassium less than 2.5 mmol/L, or severe hyponatremia, defined as sodium less than 125 mmol/L

Other

  • Shock
  • Patients who are pregnant or breastfeeding

Who the study is looking for

  • Clinical diagnosis of acute heart failure with volume overload
  • At least 1 sign of volume overload
  • Anticipated intravenous furosemide treatment for at least 3 days
  • Age 18 years or older

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Region Syddanmark
Coordinator of this site? Confirm its status
AabenraaDenmarkRecruiting
Region Nordjylland
Coordinator of this site? Confirm its status
AalborgDenmarkRecruiting
Region Midtjylland
Coordinator of this site? Confirm its status
Aarhus NDenmarkRecruiting
Region Midtjylland
Coordinator of this site? Confirm its status
HerningDenmarkRecruiting
Region Midtjylland
Coordinator of this site? Confirm its status
HorsensDenmarkRecruiting
Region Midtjylland
Coordinator of this site? Confirm its status
Randers NoeDenmarkRecruiting
Region Syddanmark
Coordinator of this site? Confirm its status
VejleDenmarkRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.